Business Context and Reporting Period
This Form 6-K filing by CollPlant Holdings Ltd. covers the month of January 2019. The Company is a foreign private issuer focused on 3D bioprinting technologies, specifically utilizing rhCollagen-based BioInk for organ and tissue bioprinting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and strategic developments rather than financial performance.
Material Changes
- Board Resignation: David Tsur notified the Company on January 1, 2019, of his resignation as Chairman and Board member, effective March 31, 2019, or earlier upon the appointment of a successor.
- Search for Successor: The Company has formed a committee to search for a U.S.-based chairperson of the Board of Directors.
- Strategic Partnerships: The Company continues to advance its 3D bioprinting business in the U.S., building on a previously announced License, Development and Commercialization Agreement with United Therapeutics for 3D bioprinted lung transplants.
Guidance, Outlook, and Risks
Management commentary indicates a strategic focus on expanding U.S. operations and partnerships. Various companies are currently evaluating CollPlant's rhCollagen-based BioInk for bioprinting applications. No specific financial guidance, risk factors, or contingencies were disclosed in this filing.
Investor Verification Checklist
- Confirm the timeline for appointing a new U.S.-based Board Chairperson.
- Verify the status of ongoing evaluations by U.S. companies regarding CollPlant's BioInk technology.
- Review subsequent filings for the appointment of a successor to David Tsur.